ATP citrate lyase (ACLY) is an important enzyme linking carbohydrate to lipid metabolism by
generating acetyl-CoA from citrate for fatty acid and cholesterol biosynthesis. Mendelian …

Several new or emerging drugs for dyslipidemia owe their existence, in part, to human
genetic evidence, such as observations in families with rare genetic disorders or in …

Consumption of fructose has risen markedly in recent decades owing to the use of sucrose
and high-fructose corn syrup in beverages and processed foods, and this has contributed to …

Cancer cells rely on several metabolic pathways such as lipid metabolism to meet the
increase in energy demand, cell division, and growth and successfully adapt to challenging …

Chronic or non-communicable diseases are the leading cause of death worldwide; they
usually result in long-term illnesses and demand long-term care. Despite advances in …

Introduction: Tolerability problems in treating hypercholesterolemic patients undergoing
statin treatment are of growing concern to physicians and patients, thus underlining the need …

Abstract Introduction Bempedoic acid (ETC-1002) is a first-in-class lipid-lowering agent
recently approved by the United States (US) Food and Drug Administration (FDA) and the …

ATP-citrate lyase (Acly) is the target of the new class low-density lipoprotein-cholesterol
(LDL-C)-lowering drug bempedoic acid (BA). Acly is a key metabolic enzyme synthesizing …

Diabetic kidney disease (DKD) is a major microvascular complication of diabetes mellitus
(DM) that poses a serious risk as it can lead to end-stage renal disease (ESRD). DKD is …

Despite the widespread use of statins and ezetimibe to decrease low-density lipoprotein
cholesterol (LDL-C) levels and associated atherosclerotic cardiovascular disease (ASCVD) …